![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » China Approves Imports of J&J’s Tremfya
China Approves Imports of J&J’s Tremfya
January 6, 2020
China’s National Medical Products Administration has cleared Johnson and Johnson’s Tremfya (guselkumab) for importation.
The agency approved the drug for treatment of moderate-to-severe plaque psoriasis in adults who are suitable for systemic therapy.
J&J is positioning Tremfya as an alternative to Novartis’ Cosentyx (secukinumab), one of the top selling psoriasis treatments.
Upcoming Events
-
21Oct